IP-K, Sanofi Aventis Korea to conduct new research collaboration to combat HBV

Published: 2013-02-07 06:56:00

Updated: 2013-02-07 06:56:00

Hepatitis B, one of the most common and serious infectious diseases, will be targeted in a new collaborative venture between Institut Pasteur Korea (IP-K) and the Korean arm of the leading global healthcare company, Sanofi-Aventis Korea.

The goal is to develop and validate a high throughput a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK